Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Domingo Domenech Eva, Juan-Manuel Sancho, Eva González-Barca, Nicholas Kelleher, Marta Rodriguez-Luaces, Jordina Rovira Sole, Silvia Verdesoto, Maite Encuentra, Damir Blazevic, Ana C Oliveira, Lourdes Escoda, Josep-Maria Ribera, Anna Sureda

Blood (2021) 138 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2021-149506

Published: 2021

Journal Articles

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

Blood (2021) 137 (7): 994–999.

https://doi.org/10.1182/blood.2020005823

Published: 2021

Includes: Supplemental data

Journal Articles

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

David Jiménez Ruiz De La Torre, MD, Gladys Ibarra, MD, Maite Encuentra, Laura Abril, MD, Albert Oriol, MD, Josep-Maria Ribera, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 5568.

https://doi.org/10.1182/blood-2019-130107

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

Journal Articles

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Maria Queralt Salas Gay, MD, Santiago Mercadal, MD, Eva Domingo Domenech, MD, Ana C Oliveira, MD PhD, Maite Encuentra, Fina Climent, MD PhD, Cristina Baca Cano, MD, Marcio Andrade-Campos, MD PhD, Esmeralda De la Banda, MD, Carmen Aguilera, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 4151.

https://doi.org/10.1182/blood.V130.Suppl_1.4151.4151

Published: 2017

Journal Articles

Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis

Helena Pomares, Isabel Sánchez-Ortega, MD PhD, Javier Grau, MD PhD, Esther Alonso, Maite Encuentra, Anna Sureda, Montserrat Arnan Sangerman

Blood (2017) 130 (Supplement 1): 2968.

https://doi.org/10.1182/blood.V130.Suppl_1.2968.2968

Published: 2017

Journal Articles

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Eva Gonzalez-Barca, MD PhD, Maria Queralt Salas Gay, MD, Francisco Javier Capote Huelva, Jose Gomez Codina, Carlos Panizo, MD PhD, Antonio Salar, MD PhD, Eva Domingo Domenech, MD, Alicia Bailen, Josep-Maria Ribera, MD, Andres Lopez, Javier Briones, MD, Andres Muñoz, Maite Encuentra, Alberto Fernandez de Sevilla, MD PhD

Blood (2017) 130 (Supplement 1): 1545.

https://doi.org/10.1182/blood.V130.Suppl_1.1545.1545

Published: 2017

Journal Articles

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Ana C Oliveira, MD PhD, Esmeralda De la Banda, MD, Eva Domingo Domenech, MD, Isabel Granada, PhD, Alberto Fernandez de Sevilla, MD PhD, Santiago Mercadal, MD, Marcio Andrade-Campos, MD PhD, Maite Encuentra, Carmen Aguilera, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 5142.

https://doi.org/10.1182/blood.V130.Suppl_1.5142.5142

Published: 2017

Journal Articles

Improving Risk Stratification of Patients with Myelodysplastic Syndromes By the Integration of Red Blood Cell Transfusion Dependency into the Revised International Prognostic Scoring System

Montserrat Arnan, Helena Pomares, Isabel Sánchez-Ortega, MD PhD, Ester Alonso, MD, Maria Condom, Maite Encuentra, Javier Grau, Anna Sureda, MD PhD

Blood (2016) 128 (22): 3178.

https://doi.org/10.1182/blood.V128.22.3178.3178

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Blood (2015) 126 (23): 1514.

https://doi.org/10.1182/blood.V126.23.1514.1514

Published: 2015

Journal Articles

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Arianne Pérez-García, Rafael De la Cámara, Jose Román-Gómez, Antonio Jiménez-Velasco, Maite Encuentra, Jose B. Nieto, Javier de la Rubia, Alvaro Urbano-Ispizúa, Salut Brunet, Arturo Iriondo, Marcos González, David Serrano, Ildefonso Espigado, Carlos Solano, Josep M. Ribera, Josep M. Pujal, Montserrat Hoyos, David Gallardo, the GVHD/Immunotherapy Committee of the Spanish Group of Hematopoietic Stem Cell Transplantation

Blood (2007) 110 (1): 461–467.

https://doi.org/10.1182/blood-2007-01-069781

Published: 2007

Includes: Supplemental data

NARROW

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Epigenetic loss of m 1 A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Prognostic VALUE of EARLY Drop in the Platelet Counts in Patients with VERY Low, Low and Intermediate Risk IPSS-R Myelodysplastic Syndromes. Results from a Single Center Analysis

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Improving Risk Stratification of Patients with Myelodysplastic Syndromes By the Integration of Red Blood Cell Transfusion Dependency into the Revised International Prognostic Scoring System

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only